Press release
Sep 19, 2018

Sosei’s Strategic Minority Investment Company, MiNA Therapeutics, Announces Update From MTL-CEBPA Clinical Trial in Patients with Advanced Liver Cancer at International Liver Cancer Association Conference

Tokyo, Japan and London, UK, 19 September 2018 – Sosei Group Corporation (“Sosei” or the “Company”; TSE Mothers Index: 4565), the world leader in GPCR medicine design and development, announces that MiNA Therapeutics has provided an update from its ongoing Phase I study of small activating RNA (“saRNA”) candidate MTL-CEBPA in advanced liver cancer patients. The update was presented at the International Liver Cancer Association Conference, held in London, UK.

Please refer to the full release on the News & Events section of MiNA Therapeutics’ website here